API | robatumumab

robatumumab Report issue

Biologics mAb Experimental

AACT ChEMBL DrugBank MeSH

Active Ingredient History

NOW

Robatumumab is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
robatumumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Insulin-like growth factor 1 receptor (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

19d12 | robatumumab | sch717454 | sch 717454 | sch-717454

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Bone Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 2)

Kidney Diseases (Phase 1)

Neoplasms (Phase 1/Phase 2)

Neuroblastoma (Phase 1)

Neuroectodermal Tumors, Primitive, Peripheral (Phase 2)

Osteosarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue